Karen Frances Yates

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

Tioga Pharmaceuticals, Inc. manufactures pharmaceutical products. It develops therapies for the treatment of pruritus. The company was founded by Stuart J. Collinson in 2005 and is headquartered in San Diego, CA.

Exploramed NC7, Inc. manufactures wearable breast pumps. It also offers milk bags and accessories, such as flange, flextube, and charger. The company was founded by Josh Makower in 2014 and is headquartered in Mountain View, CA.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ.

Vistakon, Inc. manufactures disposable contact lenses. The company's products include daily wear disposable and bifocal lenses. It also makes color contact lenses (in shades of blue, green, gray and honey). Vistakon is headquartered in Jacksonville, FL.

BioMedInvest AG I invests in companies located in Switzerland, Germany, Austria, France and Italy. The fund targets companies operating in the fields of drug development, focusing less on diagnostics and medical technology. It acts as lead/co-lead investor and provides financing for start-up to later stage and spin-off capital requirements with an investment size of CHF1 - CHF10 million.

Part of Bellevue Group AG, Biotech Ventures GP Ltd. is a venture capital fund. The company is based in St. Peter Port, UK.

BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993.

Willow Laboratories & Medical Center provides clinical and forensic toxicology laboratories services. The company was founded in 1995 by Brian J. Strasnick and is headquartered in Lynn, MA.

Blue River PetCare LLC owns and operates a multi-state veterinary hospital. It offers pet healthcare service. The company was founded by Daniel Blumenthal, Roy Jain and Ferdie Schmitz in 2009 and is headquartered in Chicago, IL.

RusnanoMedInvest (RMI) is a subsidiary of RUSNANO, a 100 percent Russian state-owned company whose mission is to develop the Russian nanotechnology industry through co investment in nanotechnology projects with substantial economic potential or social benefit. RMI was founded in 2012 headquartered in Russian. The firm to realize advanced projects in medicine and pharmaceuticals involving the transfer of intellectual property rights and modern pharmaceutical production technology to Russia.

Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.

Day Zero Diagnostics, Inc. operates as an infectious disease diagnostic firm. It develops technologies to modernize the treatment for infectious diseases. The company was founded by Jong Leeis, Miriam Huntley, Doug Kwon, Melis Anahtar, and Dougal Maclaurin and is headquartered in Boston, MA.

Brilliant Home Technology, Inc. manufactures electronic products. Its products include single switch, two switches, three switches and four switches. The company was founded by Aaron Emigh, Steven Stanek, and Jeremy Hiatt in 2014 and is headquartered in San Mateo, CA.

PathAI, Inc. provides artificial intelligence powered technology for the pathology laboratory. It offers research and drug development, clinical and global health solutions. The firm specializes in pathology, digital pathology, oncology, immune-oncology, auto immune disease, neurodegenerative disease, companion diagnostics, precision medicine, solutions, research and development and computational pathology. The company was founded by Andrew H. Beck and Aditya Khosla in 2016 and is headquartered in Cambridge, MA.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Team Better, LLC develops mobile software applications. The private company is based in Encinitas.

Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber.

Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.

Kids Care Holdco LLC provides health care service. The company is headquartered in Chicago, IL.

Mirvie, Inc. provides precise, actionable, non-invasive tests for maternal-fetal health. The company is headquartered in South San Francisco, CA.

Strong Room Technology Pty Ltd. provides electronic controlled drug register (ECDR), opioid replacement therapy (OTP/ORT), staged supply, e-prescribing, administration reporting, pharmacy ward theatre configuration & notification, and enterprise reporting. The company is based in Melbourne, Australia. The Australian company's system uses human-centric design principles and has adjustable modules for medication management based on context and care provider needs. The company prioritizes user feedback in product development to ensure that their products, tools, systems, and platform align with customer needs and preferences through customer co-creation. The company was founded in 2017 by Mark Feldschuh, Max Mito, Chris Durre, Kieran Start. Max Mito has been the CEO since 2017.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.